Soluble receptor for advanced glycation end products (sRAGE) attenuates haemodynamic changes to chronic hypoxia in the mouse
David GS Farmer, Marie-Ann Ewart, Kirsty M Mair, Simon Kennedy
Pulmonary Pharmacology & Therapeutics | ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD | Published : 2014
The calgranulin-like protein MTS1/S100A4 and the receptor for advanced glycation end-products (RAGE) have recently been implicated in mediating pulmonary arterial smooth muscle cell proliferation and vascular remodelling in experimental pulmonary arterial hypertension (PH). Here, the effects of RAGE antagonism upon 2 weeks of hypobaric hypoxia (10% O2)-induced PH in mice were assessed. Treatment with sRAGE was protective against hypobaric hypoxia-induced increases in right ventricular pressure but distal pulmonary vascular remodelling was unaffected. Intralobar pulmonary arteries from hypobaric hypoxic mice treated with sRAGE showed protection against a hypoxia-induced reduction in complianc..View full abstract
This study was supported by the Integrative Mammalian Biology Initiative - jointly funded by the BBSRC and MRC.